Head-to-head · free
KITZ CORPORATION vs ResMed
6498.T vs RMD — return on capital, cash generation, margins and balance sheet side by side.
6498.T
2 / 3
measures where 6498.T leads
RMD
1 / 3
measures where RMD leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | 6498.T · FY2025 | RMD · FY2026 |
|---|---|---|
| Revenue | $176.7B | $5.7B |
| Net income | $11.5B | $1.5B |
| Revenue growth (yearly, multi-year) | 2.7% | 12.1% |
| Free cash flow | — | $1.6B |
| Free cash flow margin | — | 29.2% |
| Net cash / (debt) | — | — |
| ROIC | — | 20.7% |
| Return on equity | — | 24.3% |
| Gross margin | — | 61.1% |
| Operating margin | — | 33.8% |
| Net debt / EBITDA | — | -0.38x |
Figures are as reported by each company; latest fiscal year shown.
Where KITZ CORPORATION's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where ResMed's cash went (FY2026)
- Capital spending
- $156.3M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free